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Summary A highly sensitive system was previously developed by us to detect the presence of colorectal carcinoma cells in blood in the form
of cytokeratin 20 (CK20) mRNA. In the present study, we used an improved version of this system to analyse the peripheral blood of 28
patients with colorectal carcinoma, five patients with non-cancerous intestinal diseases and six normal controls for the presence or absence
of CK20 mRNA and to investigate the relationship between the mRNA results and prognosis. All eight patients with recurrence were positive
for CK20 mRNA, as were four patients in the Dukes' C stage with either distant metastasis or dissemination. Five of the nine patients in the
Dukes' C stage with neither distant metastasis nor dissemination were positive, and three of these developed recurrence within 11 months
after the analysis. Only one of the seven patients in the Dukes' A or B stage was positive, and none showed recurrence during the 1-19
months of observation. None of the five patients without carcinomas or of the six normal controls was positive. Although the follow-up period
is limited and the recurrences were all local at present, these results suggest that the presence of CK20 mRNA in circulation may be a useful
indicator for the screening of advanced colorectal carcinoma patients with a high risk of recurrence.
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A high incidence of haematogenous dissemination is one major
obstacle in curative surgery for colorectal carcinoma (Taylor et al,
1996). However, it is not easy to identify patients with a high risk
of recurrence or metastasis. Patients with Dukes' C disease have
metastases in adjacent lymph nodes and therefore possess clones
of malignant cells with the ability to spread via the lymphatic
system into adjacent lymph nodes and to grow there (Taylor et al,
1996). But this is a very general view because some patients in the
Dukes' B stage develop recurrence and some in the Dukes' C stage
do not. If we were able to obtain more direct evidence of a high
possibility of recurrence in individual cases before operation or
during the follow-up period, it would be very useful for selecting
patients who need careful follow-up and adjuvant chemotherapy.
Therefore, the presence ofcancer cells in circulation would consti-
tute far more direct evidence for a high possibility ofrecurrence or
metastasis.
We focused on CK20 as a marker for the detection of the pres-
ence ofcolorectal carcinoma cells. CK20 is an intermediate-sized
filament and its expression is almost entirely confined to the
gastric and intestinal epithelium, urothelium and Merkel cells,
indifferent to normal or malignant (Moll et al, 1982, 1992). As for
colorectal adenocarcinomas, CK20 is expressed in more than 90%
of all cases, regardless ofthe grade ofdifferentiation, and even in
metastatic tumours (Moll et al, 1992, 1993). We therefore decided
to determine the presence of colorectal carcinoma cells in the
peripheral blood by targeting CK20 mRNA. Although Burchill et
al (1995) have shown that this is possible by using a high-CK20-
expressing colon carcinoma cell line mixed into a healthy donor's
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blood, its sensitivity was as low as 100 cells per 1 ml of blood
(Burchill et al, 1995). However, we previously designed a system
to detect the presence ofhepatocellular carcinoma cells in circula-
tion in the form of ax-fetoprotein mRNA (Funaki et al, 1995,
1997a) and another to detect the presence ofpancreatic and gastric
carcinoma cells in circulation in the form of carcinoembryonic
antigen mRNA (Funaki et al, 1996). By using these techniques as
well as Burchill's primers as the first-step primers, we developed a
highly sensitive reverse transcription (RT) and three-step nested
polymerase chain reaction (PCR) method that was able to detect
the presence of CK20 mRNA even in a healthy donor's blood
containing only a single CK20-expressing cell (Funaki et al,
1997b). In addition, as our original 3' primer used in the second
and third steps could not anneal with the genomic sequence, the
specificity of the nested PCR product was always satisfactory on
sequencing. After we ascertained that this system did work in
actual patients' blood samples, we further improved our RT-PCR
method in the present study by reducing the quantity of the PCR
mixture and the time necessary for PCR, and analysed various
patients' blood samples to determine the relationship between the
PCR results and recurrence or metastasis.
PATIENTS AND METHODS
Patients
All carcinoma patients' profiles are listed in Tables 1-4. As
controls, we analysed five patients with non-cancerous intestinal
diseases, listed in Table 5, and also six healthy volunteers as
normal controls. Diagnosis of recurrence was made by echo-
graphy, computerized tomography, chest radiography and, if
necessary, angiography and scintigraphy. After surgery, adjuvant
chemotherapy was performed on all patients in the Dukes' C stage
and patients with poorly differentiated carcinoma (patient no. 22).
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Table 1 List of patients with recurrence at the time of analysis
Sex/age (years) Site of Dukes' stage at Duration after Site of CK20 Outcome after operation
Patient no. at analysis carcinoma primary operation recent therapy recurrence mRNA for recurrence
1 M/54 Rectum C 18 months after Liver + Not operated
PEITa
2 M/68 Rectum A 19 months after Distant + Not operated
operation lymph nodes
3 F/68 Rectum C 55 months after Local + Not operated
operation
4 M/63 Rectum C 36 months after Liver + Not operated
operation
5 M/53 Rectum A 13 months after Local + 2 months after total
operation pelvic exenteration
recurrence (inguinal
lymph nodes)
6 F/61 Colon C 11 months after Liver + 11 months after
operation hepatectomy
recurrence (liver)
7 M/40 Colon C 7 months after Lung + Not operated
reoperation for
local recurrence
8 F/57 Colon C 24 months after Liver and lung + Not operated
operation
aPEIT, percutaneous ethanol infusion therapy.
Table 2 List of preoperatively analysed patients in Dukes' C stage with either distant metastasis or peritoneal dissemination
Patient no. Sex/age (years) Site of Metastasis or Operation CK20 Outcome after
at analysis carcinoma dissemination performed mRNA resection
9 M/69 Rectum Para-aortic lymph nodes Anterior resection After 2 months
+ metastasis to
Virchow's lymph nodes
10 F/58 Rectum Right kidney and liver Anterior resection + Within 1 month lung
metastasis
11 M/54 Colon Liver Sigmoidectomy and hepatectomy + After 11 months bone
metastasis
12 F/72 Colon Peritoneal dissemination Not resected + Not resected
Ethical consideration
This study was performed after obtaining the patients' informed
consent, andthe study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki and the guidelines of the
ethical committee of Kyoto University.
RNA extraction and cDNA synthesis
RNA was extracted from peripheral venous blood according
to the acid guanidinium-phenol-chloroform (AGPC) method
(Chomczynski et al, 1987) with a slight modification. In short,
5 ml ofheparinized whole blood was thoroughly mixed with 5 ml
of a guanidinium isothiocyanate-enriched solution D (6M
guanidinium isothiocyanate, 25 mm sodium citrate, pH 7.0, 0.5%
Sarcosyl, 100 mm [-mercaptoethanol). We increased the quantity
of guanidinium isothiocyanate (Funaki et al, 1995, 1996, 1997a
and b) forbetterprotection ofRNA in the whole blood, as reported
by Gillespie et al (1994). Two millilitres of this sample mixture,
which corresponds to 1 ml of total blood, was further processed
with the usual AGPC method. Extracted RNA was solubilized in
diethyl pyrrocarbonate (DEPC)-treated water and was reverse
transcribed in a 50-gl mixture consisting of 10gl of 5 x buffer
(Gibco, Gaithersburg, MD USA), 2 mM dNTP (Wako Pure
Chemical Industries, Osaka, Japan), 10 mm DTT (Gibco BRL),
0.25 gg randomhexamer(PharmaciaBiotech, Tokyo, Japan), 5 Ag
bovine serum albumin (BSA) (Gibco BRL) and 200 U M-MLV
reverse transcriptase (Gibco, cat. no. 28025-013). The reverse
transcription was performed at 37°C for 1 h.
Preparation of positive control template
A human colon cancer cell line, Colo 205 (purchased from
American Type Cell Culture) (Semple et al, 1978), was cultivated
in Dulbecco's modified eagle medium supplemented with 10%
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Table 3 List of patients in Dukes' C stage with neither distant metastasis nor dissemination
Patient no. Sex/age (years) Site of Time of CK20
at analysis carcinoma Operation performed analysis mRNA Outcome
13 M/60 Rectum Rectal amputation Prea + After 20 months recurrence (-)
14 M/76 Rectum Anterior resection Pre + After 16 months recurrence (-)
15 M/49 Rectum Rectal amputation Pre + After 7 months recurrence (local)
16 M/46 Rectum Anterior resection Pre - After 2 months recurrence (-)
17 M/78 Rectum Anterior resection Pre - After 1 month recurrence (-)
18 F/39 Colon Sigmoidectomy Pre + After 11 months recurrence (local)
19 M/54 Colon Sigmoidectomy Pre - After 3 months recurrence (-)
20 M/52 Colon Sigmoidectomy Pre - After 3 months recurrence (-)
5 months after
21 M/54 Rectum Anterior resection operation + After 1 month recurrence (local)
aPre, analysis performed 1 or 2 days before surgery.
Table 4 List of preoperatively analysed patients in Dukes' A or B stage
Patient no. Sex/age (years) Site of Dukes' CK20
at Analysis carcinoma Stage Operation performed mRNA Outcome
22 F/80 Rectum B Anterior resection + After 19 months recurrence (-)
23 M/53 Rectum A Rectal amputation - After 18 months recurrence (-)
24 M/81 Rectum B Pelvic exenteration - After 3 months recurrence (-)
25 M/57 Rectum A Anterior resection - After 2 months recurrence (-)
26 M/58 Colon B Sigmoidectomy - After 18 months recurrence (-)
27 M/61 Colon B Sigmoidectomy - After 2 months recurrence(-)
28 F/75 Colon A Sigmoidectomy - After 1 month recurrence (-)
Table 5 Patients with non-cancerous intestinal diseases
Patient no. Sex/age (years) at CK20
analysis Disease Time of analysis mRNA
29 M/69 Radiation colitis Before operation -
30 M/65 Rectal leiomyosarcoma with Before operation -
lung metastasis
31 M/71 Rectal carcinoid Before operation -
32 M/28 Crohn's disease Before operation -
33 M/31 Acute appendicitis with 3 days after operation -
panperitonitis
fetal bovine serum. mRNA was extracted from Colo 205 cells
using aQuickPrep R mRNApurification kit (PharmaciaBiotech),
followed by reverse transcription performed with 1 gg of mRNA
as described in the preceding section.
PCR primers
The specific primers for CK20 gene detection were synthesized
according to the published sequence (Moll et al, 1993). Sense
primer 1 (5'-CAGACACACGGTGAACTATGG-3') within exon 1
and antisense primer 2 (5'-GATCAGCTTCCACTGTTAGACG-
3') within exon 3 are both identical to the published sequences of
Burchill et al (1995). For the nested PCR, we used an original
sense primer 3 (5'-CTGTTTGTTGGCAATGAGAAAATGG-3')
within exon 1 and an original antisense primer 4 (5'-GTATTC-
CTCTCTCAGTCTCATACT-3') covering both exon 2 (the 3' two
bases, C and T) and exon 3; therefore, primer 4 could not anneal
with the genomic DNA (Funaki et al, 1997b).
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PCR protocol
We further improved the PCR method on the basis of our previ-
ously developed method. First, PCR was performed by using
primers 1 and 2, which amplify a 370-bp fragment as reported by
Burchill et al (1995). We previously reported using a 100-g1
mixture for this step (Funaki et al, 1997b), but we reduced the
total volume to 50 p1, consisting of one half of the reverse-
transcribed sample (25 pl) and 5 pl of 10 x PCR buffer (Perkin
Elmer Cetus, Norwalk, CT, USA), 50 pmol of each primer, 1 jg
of BSA, 0.2 mm dNTP and DEPC-treated water. This reduction
in the sample volume enabled us to reduce the quantity of the
individual constituents and to shorten the time necessary for
PCR. The reaction mixture was overlaid with mineral oil, heat
denatured at 930C for 5 min and then cooled to 80°C for the
addition of2.5 units of Taqpolymerase (AmpliTaq, Perkin Elmer
Cetus). This first-step PCR consisted of a 1-s denaturing step
(94°C), followed by a 20-s annealing step (63°C) and then by a
10-s chain extension (72°C). After 35 cycles, 1 pl of the PCR
product was used as the template for the second PCR. The
second set of primers consisted of primers 1 and 4, which
amplify a 349-bp fragment (Funaki et al, 1997b). The 50 p1 of
the second-step PCR mixture was basically the same as that of
the first-step PCR except for the different primers and the
addition of 24 pl of DEPC-treated water. The protocol for the
second-step PCR was the same as for the first-step. After 35
cycles, 1 pl ofthis second-step product was used as the template
for the third-step PCR. The third set of primers consisted of
primers 3 and 4, which amplify a 303-bp fragment (Funaki et al,
1997b). The constituents ofthe third-step PCR were basically the
same as those ofthe second PCR mixture except for the different
template and primers. The amplification procedure for the third
PCR was also basically the same as for the first PCR except for
the annealing temperature, which was set at 62°C. Then, 10 p1
of the PCR product was subjected to electrophoresis on
2.5% agarose gels (Agarose NA, Pharmacia Biotech) containing
20 ng ml-' ethidium bromide.
To test the reliability of RNA extraction, a 319-bp f-actin
cDNA fragment was amplified by using the 50-pmol-each primer
pair reported by Fuqua et al (1990). The PCR template consisted
ofthe remaining halfofthe sample cDNA. The constituents ofthe
PCR mixture were the same as those of the mixture for CK20
mRNA except for the different primers. Except for the annealing
temperature (550C) calculated from the primer sequences, our
PCR protocol for the detection ofthe0-actin cDNA fragment was
the same as that for the detection of the CK20 cDNA fragment.
When the 35-cycle amplified band was faint, 2% of the PCR
product (corresponding to 1 p1) was amplified in a new PCR
mixture for 30 cycles, using the same primer set with the same
programme. We were able to observe the amplification of0-actin
mRNA in all the samples from both patients and controls (data
not shown).
The positive control for CK20 mRNA detection was the PCR
performed in the same manner as the individual-step protocol, but
as a single step, using 0.1,Ig of Colo 205-derived cDNA as the
template. The negative control for the first step was the PCR
simultaneously performed without any template. The negative
controls for the second and third steps were the nested PCR
products performed in the same way as the sample PCR using
the previous negative control sample as the template.
Third-step N_
Third-step P _
Second-step N -_
Second-step P
First-step N _
First-step P_ _
100-bp ladder-
Figure 1 Results of PCR performed according to the improved protocol.
Each step was performed as a single-step PCR. P indicates PCR with 0.1 jg
of Colo 205 cDNA and N shows PCR performed without template
RESULTS
Confirmation of the efficiency of the improved PCR
protocol
As can be seen in Figure 1, the first, second and third PCR prod-
ucts were visible as individually distinct, single bands. To deter-
mine the sensitivity ofthe newly improvedprotocol, weperformed
the same dilution study as we did to test our original method. In
short, we serially diluted the first-step PCR product obtained by
using 0.1jIg ofColo 205-derived cDNA as the template and then
performed the second-step PCR. Then, 1 gl of this second-step
PCR product was used for the third-step PCR. The present
protocol visualized a sample diluted up to 10-8, the same sensi-
tivity as obtained with the previous three-step PCR (data not
shown). Thus, the efficiency and the specificity of the PCR using
the present time-saving and less expensive protocol was the same
as for our previous procedure.
Detection of CK20 mRNA in patients' samples
All eight patients who already had recurrence at the time of this
analysis were positive for CK20 mRNA in their peripheral
venous blood (Table 1). Among these eightpatients, patient no. 6,
who underwent this analysis before liver resection for metachro-
nous liver metastasis, was positive for CK20 mRNA and devel-
oped a second liver metastasis 11 months after this analysis.
Patient no. 5, who underwent this analysis before pelvic exentera-
tion for local recurrence, was also positive for CK20 mRNA, and
metastatis was found in the inguinal lymph nodes 2 months after
surgery. All four preoperatively analysed patients who were
found to be in Dukes' C stage with either distant metastasis or
peritoneal dissemination were positive for CK20 mRNA in their
blood (Table 2). One ofthese fourpatients underwent resection of
both the colon and the metastatic portion of the liver, but devel-
oped bone metastasis after 11 months. Of the nine patients in
Dukes' C stage with neither distant metastasis nor peritoneal
dissemination at the time of surgery, five patients were positive
for CK20 mRNA before surgery. Three of these five developed
recurrence after 1, 7 and 11 months respectively (Table 3 and
Figure 2). The remaining six patients were recurrence free for
1-20 months after surgery (Table 3). Only one of the seven
patients in Dukes' A or B stage was positive for CK20 mRNA
before surgery, but none ofthem developed recurrence during the
1-19 months ofobservation (Table 4).
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Negative control_
Healthy volunteer1 -*
Patient 30-_
Patient 29_
Patient 21
Patient 20 _
Patient 19 -_
Patient 18 -_
Patient 17 _
Patient 16 _
Patient 15 _
Patient 14 -*-
Patient 13 _0
3-4 _0
100-bp ladder -_
Figure 2 Results of three-step PCR of blood samples of patients in Dukes'
C stage without distant metastasis or dissemination (patients nos. 13-21),
patients with non-cancerous intestinal diseases (patients nos. 29 and 30) and
a healthy volunteer. 3-4 designates third-step positive control with primers
3 and 4
None of the five patients with intestinal diseases without carci-
nomas (Table 5) or of the six healthy volunteers (data not shown)
was positive.
All original colorectal carcinomas of ten patients negative for
CK20 mRNA in their blood were positive for CK20 mRNA by
RT-PCR (data not shown).
Sequencing of the final PCR products of the positive control
sample and ofthe randomly chosen patients' samples revealed that
the amplified products were consistently identical with the CK20
cDNA sequence (data not shown).
DISCUSSION
In the present study, we aimed at a more practical application of
our system by reducing the time and the quantity of individual
constituents necessary for three-step PCRs. After this modifica-
tion, the time necessary to obtain the final result was shortened
from 9 to 8 h without any reduction in the high sensitivity and
specificity and at a lower cost.
As we previously mentioned, the possibility of contamination
by a few normal epithelial cells cannot be ruled out because ofthe
lack of a definite marker to discriminate between carcinoma cells
and non-cancerous cells (Funaki et al, 1995, 1996, 1997a and b).
However, non-cancerous epithelial cells cannot live long without
anchoring, and our analysis showed that the five patients with non-
cancerous intestinal diseases, including inflammatory diseases,
and the six normal controls were negative for CK20 mRNA.
Positive CK20 mRNA in blood may thus be considered to indicate
the presence ofcarcinoma cells in blood.
The analysis of actual patient blood samples demonstrated that
all patients with recurrence, distant metastasis or dissemination
were positive for CK20 mRNA in blood. In addition, of the nine
patients in Dukes' C stage without distant metastasis or dissemina-
tion at surgery, five were positive for CK20mRNA in blood before
or after surgery, and three of them later developed recurrence.
Although the follow-up period is limited and the clinical applica-
tion ofthis test may be limited to patients in advanced stages, these
findings indicate that the detection of the presence of CK20
mRNA in blood seems to precede the clinical manifestation of
recurrence. For this reason, patients with CK20 mRNA in blood
may be suitable candidates for intensive chemotherapy to prevent
formation of the clinically detectable secondary foci. Ongoing
repetitive analysis after surgery for a longer period should clarify
by how many months the appearance of CK20 mRNA in blood
precedes the clinical manifestation ofrecurrence.
One Dukes' B patient and two Dukes' C patients were positive
for CK20 mRNA in blood but without recurrence during the obser-
vation period. The Dukes' B patient was the only case of poorly
differentiated carcinoma of all the patients in Dukes' A and B
stages and those in Dukes' C stage but without distant metastasis
or dissemination. There are several possible explanations for these
results. First, their carcinoma cells have been growing more slowly
Second, as all Dukes' C patients and patients with poorly differen-
tiated carcinomas received chemotherapy, these patients may have
responded unusually well to the treatment. Finally, their cancer
cells may have expressed fewer adhesion molecules or molecules
necessary for cell-to-cell interaction, such as E-cadherin (Mayer et
al, 1993a) or CD44 (Mayer et al, 1993b), on their surface. As we
cannot collect viable, circulating carcinoma cells enough for the
above-mentioned analysis at present, the precise reason for
individual results remains unclear. Analysis of more cases and
observation for a longer period should provide more information.
It is noteworthy that recurrence appeared later in three CK20
mRNA-positive patients, which manifested as 'local recurrence'
(patients nos. 15, 18 and 21 in Table 3), and that two patients with
local recurrence were positive for CK20 mRNA (patients nos. 3
and 5 in Table 1). Patients with local recurrence but without
distant metastasis or dissemination often undergo pelvic exentera-
tion (Pearlman et al, 1987). But if these patients are positive for
CK20 mRNA in blood, the patients possess haematogenously
disseminating carcinoma cells and thus may incur re-recurrence
or metastasis even after pelvic exenteration. In fact, patient no. 5
with local recurrence was positive for CK20 mRNA in blood
before total pelvic exenteration and developed recurrence in the
inguinal lymph nodes 2 months after the reoperation. As for this
formation of a secondary focus at the site where the primary
carcinoma existed, there are at least two possible explanations.
One is that the local recurrence was caused by the circulating
carcinoma cells; that is, they preferentially returned to the 'locus'
where they used to locate and formed the secondary focus
(Togo et al, 1995). The other is that the circulating carcinoma
cells originated from local recurrences; that is, the minute
secondary foci were growing gradually and from there the cells
moved into the blood vessels. The first explanation may well
apply to preoperatively CK20 mRNA-positive patients and the
second to patient no. 5 and in particular patient no. 21. The latter
patient was analysed as positive for CK20 mRNA 5 months after
surgery, and clinically detectable local recurrence was found
1 month later. The detection of CK20 mRNA in the peripheral
blood thus seems to also provide an insight into the manner in
which colorectal carcinoma spreads.
In conclusion, the presence of CK20 mRNA in the peripheral
blood of advanced colorectal carcinoma patients seems to repre-
sent an indicator ofpossible recurrence in individual patients.
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